-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Adverum Biotechnologies, Maintains $33 Price Target

Benzinga·05/15/2025 15:33:24
Listen to the news
Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $33 price target.